Gene · 55867
SLC22A11: solute carrier family 22 member 11
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SLC22A11: solute carrier family 22 member 11. Genes, record 55867. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/55867
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NSA0 | Solute carrier family 22 member 11 | 550 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 64180 | Q9NSA0 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 4050 | Q9NSA0 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 4050 | Q9NSA0 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 80760 | Q9NSA0 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 4460 | Q9NSA0 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 183731 | Q9NSA0 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 10384 | Q9NSA0 | Espacenet |
| WO 2019183292 A1 | 2019-09-26 | 18 | Q9NSA0 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 244615 | Q9NSA0 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 244615 | Q9NSA0 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| PROBENECID | CHEMBL897 | Solute carrier family 22 member 11 inhibitor | INHIBITOR |
Source ChEMBL
Trials16
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07118618 | PROBENECID | PHASE2 | ClinicalTrials.gov | |
| NCT07092813 | PROBENECID | PHASE1 | ClinicalTrials.gov | |
| NCT05903859 | PROBENECID | PHASE3 | ClinicalTrials.gov | |
| NCT05442983 | PROBENECID | PHASE2 | ClinicalTrials.gov | |
| NCT04551222 | PROBENECID | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT04218357 | PROBENECID | PHASE1 | 2025-02-27 | ClinicalTrials.gov |
| NCT03357614 | PROBENECID | PHASE3 | 2020-12-29 | ClinicalTrials.gov |
| NCT02243631 | PROBENECID | EARLY_PHASE1 | 2022-07-26 | ClinicalTrials.gov |
| NCT01816646 | PROBENECID | PHASE1 | ClinicalTrials.gov | |
| NCT01320722 | PROBENECID | PHASE3 | 2017-06-29 | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsNIH grants544
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SLC22A11 papers | Newest fiscal year |
|---|---|---|---|
| R01DK109392 | The Role in OAT1 in Uremia | 8 | 2025 |
| R01HL086694 | From GWAS loci to blood pressure genes, variants & mechanisms - Renewal | 8 | 2025 |
| P30ES005022 | Rutgers Center for Environmental Exposure and Disease (CEED) | 6 | 2025 |
| P30ES007033 | University of Washington Interdisciplinary Center for Exposures, Diseases, Genomics & Environment | 5 | 2025 |
| T32ES007148 | Training in Environmental Toxicology | 5 | 2025 |
| P30ES006694 | Southwest Environmental Health Sciences Center | 4 | 2025 |
| R01AI077505 | Pharmacogenomics of HIV Therapy | 4 | 2025 |
| P30DK056350 | Nutrition Obesity Research Center (NORC) | 3 | 2025 |
| P30AI050410 | The University of North Carolina Center for AIDS Research | 2 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
1 to 10 of 544Source NIH's project files
See all 544 nih grantsPapers695
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Associations of Genetic Variants in Uric Acid Transporter Genes With Salt Sensitivity, Longitudinal Blood Pressure Changes, and Incident Hypertension in Chinese Adults. | J Clin Hypertens (Greenwich) | 2026 | 42745169 | PubTator, text mining | PubMed |
| Comparison of the permeability of RdRp inhibitors, remdesivir, molnupiravir and azvudine, in placental barrier cell models and exploration of their transport mechanisms. | J Antimicrob Chemother | 2026 | 42497385 | PubTator, text mining | PubMed |
| Comparison of the permeability of DPP-4 inhibitors-sitagliptin, vildagliptin, linagliptin, and alogliptin-in placental barrier cell models and exploration of their transport mechanisms by LC-MS/MS. | BMC Pregnancy Childbirth | 2026 | 42443801 | PubTator, text mining | PubMed |
| Urine-to-Blood Partitioning of Per- and Polyfluoroalkyl Substances in Human Biomonitoring: Implications for Environmental Exposure Analysis and Bioaccumulation Assessment. | Molecules | 2026 | 42280183 | PubTator, text mining | PubMed |
| Regulation of Human Renal Transporters by Pregnancy-Related Hormones in Primary Proximal Tubular Epithelial Cells. | Metabolites | 2026 | 42188001 | PubTator, text mining | PubMed |
| Functional characterization of human organic anion transporter 4 (hOAT4) as a pH-dependent citrate transporter in renal proximal tubules. | J Pharmacol Sci | 2026 | 41866670 | PubTator, text mining | PubMed |
| Integrated Transcriptomic and Histological Analysis of TP53/CTNNB1 Mutations and Microvascular Invasion in Hepatocellular Carcinoma. | Genes (Basel) | 2026 | 41751574 | PubTator, text mining | PubMed |
| Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters-In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling. | Clin Transl Sci | 2026 | 41630535 | PubTator, text mining | PubMed |
| Expression of drug transporters in human allogenic transplanted kidneys in acute rejection. | Toxicol Appl Pharmacol | 2026 | 41581572 | PubTator, text mining | PubMed |
| Inhibition of human organic anion transporter 4 (OAT4) activity by bisphenol analogues. | Environ Pollut | 2026 | 41407188 | PubTator, text mining | PubMed |
1 to 10 of 695
See all 695 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/55867
GET https://conductscience.org/api/genes/v1/55867/patents?page=2